Acquisitions - Narrative (Details) - USD ($)				1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 18, 2025	Jul. 01, 2025	Apr. 01, 2025	Nov. 30, 2024	Sep. 30, 2025	Mar. 31, 2025	Sep. 30, 2025	Mar. 30, 2025	Dec. 31, 2024	Mar. 31, 2024
BioCenturion
Business Combination [Line Items]
Non-controlling interest related to variable interest entity									$ 4,100,000
Ownership interest in variable interest entity						50.00%
EyeLock | BioCenturion Joint Venture
Business Combination [Line Items]
Ownership percentage in joint venture			50.00%
PAC | Onkyo Joint Venture
Business Combination [Line Items]
Ownership percentage in joint venture			77.20%
Voting interest percentage in joint venture			85.10%
Sharp | Onkyo Joint Venture
Business Combination [Line Items]
Ownership percentage in joint venture			22.80%
Voting interest percentage in joint venture			14.90%
GalvanEyes | BioCenturion Joint Venture
Business Combination [Line Items]
Ownership percentage in joint venture				50.00%
VOXX Common Stock
Business Combination [Line Items]
Shares of investment held (in shares)						6,463,808			6,463,808
Non-controlling ownership interest										29.00%
BioCenturion
Business Combination [Line Items]
Non-controlling ownership interest								50.00%
BioConnect
Business Combination [Line Items]
Purchase price		$ 13,000,000
Net sales/revenue attributable to acquiree					$ 2,500,000		$ 2,500,000
Net income (loss) attributable to acquiree					400,000		400,000
Acquisition costs incurred					200,000		400,000
Cash paid		$ 12,996,275
VOXX Common Stock
Business Combination [Line Items]
Net sales/revenue attributable to acquiree					84,900,000		163,800,000
Net income (loss) attributable to acquiree					3,700,000		(300,000)
Acquisition costs incurred					300,000		3,400,000
Purchase price per share (in dollars per share)			$ 7.5
Cash paid			$ 148,256,998
Fair value of previously held investment in VOXX			48,478,560			$ 48,500,000
Net measurement period adjustments					12,800,000		12,800,000
EyeLock
Business Combination [Line Items]
Cash paid	$ 100,000
GalvanEyes
Business Combination [Line Items]
Net sales/revenue attributable to acquiree					300,000		1,400,000
Net income (loss) attributable to acquiree					$ (400,000)		$ (2,200,000)
Cash paid				$ 2,900,000
Earn out provision period				15 years
Total earn out, maximum potential payment				$ 15,000,000
Current value of earn out				$ 1,500,000
BioCenturion
Business Combination [Line Items]
Cash paid			$ 4,100,000